ARTICLE | Company News
MRC Technology, DRI Capital deal
July 25, 2016 7:00 AM UTC
MRC Technology sold a portion of its royalty rights to Keytruda pembrolizumab to DRI Capital for $150 million. The not-for-profit said it sold a “percentage of future royalties until a pre-agreed agg...